Preeclampsia screening enhanced with serum biomarkers | USPSTF says patients should decide on prostate cancer screening | Study finds big growth in genetic testing market
ADVERTISEMENT
May 15, 2018
AACC SmartBrief
SIGN UP ⋅   FORWARD
Top Story
Preeclampsia screening enhanced with serum biomarkers
A screening method for preeclampsia that includes measurement of biomarkers in addition to the mother's risk factors outperforms a standard method, which relies on medical history and maternal characteristics. "It is now time to revise the professional guidelines and to move away from using a checklist-based method for screening," said study co-author Liona Poon.
Clinical Laboratory News (5/2018) 
LinkedIn Twitter Facebook Google+ Email
Simplify Your Lab with HORIZON Centrifuges
Effectively track cycle progress with LED lid lighting indicators. Achieve repeatability with simple "set and lock" presets, or versatility with the easily adjustable Flex featuring digital display. Drucker Diagnostics' HORIZON centrifuges are the affordable, durable choice. Learn more.
ADVERTISEMENT
Science Briefs
USPSTF says patients should decide on prostate cancer screening
The US Preventive Services Task Force issued updated recommendations urging men ages 55 to 69 to talk with doctors about prostate-specific antigen testing and then decide for themselves whether to pursue the screening. The update reflects increased use of "active surveillance" rather than aggressive treatment, mitigating the possible harms of widespread screening.
HealthDay News (5/8) 
LinkedIn Twitter Facebook Google+ Email
Study finds big growth in genetic testing market
A Health Affairs study found there are 75,000 genetic tests on the market and about 10 are added each day. The study found that spending was highest on prenatal tests, with testing for hereditary cancer coming in second, from 2014 to 2016.
MedPage Today (free registration) (5/13) 
LinkedIn Twitter Facebook Google+ Email
Malaria parasite found in animals' bone marrow
High levels of malaria parasite Plasmodium vivax were found in the bone marrow of 14 monkeys that died of malaria infections. The research suggests the need for "new diagnostic tools to estimate parasite burden in the marrow from markers in the bloodstream, as direct bone marrow diagnosis is not feasible," said Matthias Marti, lead author of the study in the journal mBio.
Center for Infectious Disease Research and Policy (5/8) 
LinkedIn Twitter Facebook Google+ Email
Online Graduate Programs Designed for Your Career
Drexel's online programs in biotechnology, clinical research, drug discovery, infectious disease, medical and healthcare simulation, and molecular medicine were developed to provide you with the education, practical skills, and competitive edge you need to be successful in your career. Learn more.
ADVERTISEMENT
Policy Briefs
Labs, other stakeholders call for progress on DAIA
Lawmakers should enact the Diagnostic Accuracy and Innovation Act, which would modernize regulation of laboratory-developed tests, in vitro diagnostics and other clinical laboratory diagnostics, according to a letter sent by a consortium of laboratories, manufacturers and advocacy groups to Congress. "As stakeholders we stand ready to continue the work necessary to finalize a consensus diagnostic reform package this year," they wrote.
360Dx (tiered subscription model) (5/10) 
LinkedIn Twitter Facebook Google+ Email
Downside-risk ACO tracks achieve savings
Accountable care organizations participating in Track 1 of the Medicare Shared Savings Program, which has no financial penalty for missing goals, have struggled to contain costs and, as a group, increased Medicare spending, while those that have taken on downside financial risk reduced federal spending. Many ACOs that failed to reach targets and instead owe money are likely to leave the program and might not have the resources to participate in any value-based care models.
Modern Healthcare (tiered subscription model) (5/12) 
LinkedIn Twitter Facebook Google+ Email
Top 5 Trends in the Pharmaceutical Industry in 2018
This white paper takes an in depth look at trends in the pharmaceutical industry that are anticipated to make a significant impact on the sector in 2018. Industry professionals can leverage this information to make the course adjustments that will give their companies a competitive edge in the market. Download the whitepaper.
ADVERTISEMENT
Practice Briefs
Zika test gains additional FDA approval
The FDA has approved the use of Roche's Cobas Zika test for streamlined screening of pooled donations of plasma and blood.
GenomeWeb Daily News (free registration) (5/14),  Reuters (5/14) 
LinkedIn Twitter Facebook Google+ Email
Business/Corporate Briefs
CareDx, Illumina sign deal on transplant clinical application products
CareDx and Illumina have reached a licensing deal on Illumina's next-generation sequencing transplant clinical application products. CareDx will be the exclusive global distributor of Illumina's TruSight HLA v1 and v2 product lines and associated software, which it plans to use for diagnostic testing for bone marrow and solid organ transplantation.
360Dx (tiered subscription model) (5/9) 
LinkedIn Twitter Facebook Google+ Email
PAVmed finalizes licensing deal for Barrett's esophagus detection tech
A definitive licensing deal was completed by PAVmed for Case Western Reserve University's EsoCheck technology, a combination of cell sampling device and DNA biomarker test designed for Barrett's esophagus detection. PAVmed has formed a subsidiary called Lucid Diagnostics, which will have the exclusive worldwide rights to the development and commercialization of the technology and all derivatives.
GenomeWeb Daily News (free registration) (5/14),  FierceBiotech (5/14) 
LinkedIn Twitter Facebook Google+ Email
Learn more about AACC:
AACC Homepage | AACC Membership | Annual Meeting
Clinical Laboratory News | Clinical Chemistry
Sign Up
SmartBrief offers 200+ newsletters
Advertise
Learn more about the SmartBrief audience
Subscriber Tools:
Contact Us:
Contributing Editor  -  Genna Rollins
Advertising  -  Wynn Hansen
P: 202.470.1149
Editor  -  April Hollis
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2018 SmartBrief, Inc.®
Privacy policy |  Legal Information